ADPT Stock Forecast 2025-2026
Distance to ADPT Price Targets
ADPT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Adaptive (ADPT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ADPT and similar high-potential opportunities.
Latest ADPT Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ADPT has a bullish consensus with a median price target of $10.00 (ranging from $7.00 to $12.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $8.42, the median forecast implies a 18.8% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sung Ji Nam at Scotiabank, projecting a 42.5% upside. Conversely, the most conservative target is provided by David Westenberg at Piper Sandler, suggesting a 16.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADPT Analyst Ratings
ADPT Price Target Range
Latest ADPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Goldman Sachs | Salveen Richter | Buy | Upgrade | $9.00 |
| Feb 20, 2025 | Piper Sandler | David Westenberg | Overweight | Reiterates | $11.00 |
| Feb 13, 2025 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $12.00 |
| Jan 28, 2025 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $7.50 |
| Dec 18, 2024 | BTIG | Mark Massaro | Buy | Maintains | $9.00 |
| Nov 11, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $7.00 |
| Oct 2, 2024 | BTIG | Mark Massaro | Buy | Maintains | $8.00 |
| Aug 2, 2024 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $6.00 |
| May 8, 2024 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $5.00 |
| Apr 4, 2024 | BTIG | Mark Massaro | Buy | Maintains | $5.00 |
| Feb 16, 2024 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $5.00 |
| Feb 15, 2024 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $8.00 |
| Nov 13, 2023 | Piper Sandler | David Westenberg | Overweight | Maintains | $6.00 |
| Oct 24, 2023 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $10.00 |
| Oct 16, 2023 | Piper Sandler | David Westenberg | Overweight | Maintains | $13.00 |
| Aug 8, 2023 | Piper Sandler | David Westenberg | Overweight | Maintains | $14.00 |
| Aug 4, 2023 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $13.00 |
| May 5, 2023 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $14.00 |
| Feb 16, 2023 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $15.00 |
| Feb 15, 2023 | Credit Suisse | Dan Leonard | Underperform | Reiterates | $7.00 |
Adaptive Biotechnologies Corporation (ADPT) Competitors
The following stocks are similar to Adaptive based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Adaptive Biotechnologies Corporation (ADPT) Financial Data
Adaptive Biotechnologies Corporation has a market capitalization of $1.29B with a P/E ratio of -7.7x. The company generates $178.96M in trailing twelve-month revenue with a -89.1% profit margin.
Revenue growth is +3.7% quarter-over-quarter, while maintaining an operating margin of -71.3% and return on equity of -62.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Adaptive Biotechnologies Corporation (ADPT) Business Model
About Adaptive Biotechnologies Corporation
Decodes genetics of the adaptive immune system.
The company develops and commercializes clinical products that leverage its immunoSEQ technology, which sequences T-cell and B-cell receptors to provide insights into the adaptive immune system. Adaptive Biotechnologies generates revenue through partnerships with pharmaceutical companies and research organizations, focusing on diagnostics and treatments for diseases like cancer and autoimmune conditions.
With a strong foundation in genomics and bioinformatics, Adaptive Biotechnologies is positioned as a leader in personalized medicine. Its innovative approach and collaborations aim to enhance diagnostic and therapeutic solutions in the healthcare industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
619
CEO
Mr. Chad M. Robins M.B.A.
Country
United States
IPO Year
2019
Website
www.adaptivebiotech.comAdaptive Biotechnologies Corporation (ADPT) Latest News & Analysis
Adaptive Biotechnologies' enhanced clonoSEQ assay for DLBCL MRD detection has received approval from New York's CLEP, offering 7-fold increased sensitivity and is covered by Medicare.
Approval of the enhanced clonoSEQ assay enhances Adaptive Biotechnologies' market position in DLBCL diagnostics, potentially boosting revenue and Medicare coverage appeal.
Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have shown varying performance relative to their sector in 2023.
Performance comparisons indicate relative strength or weakness of ADPT and CSTL against their sector, influencing investor sentiment and potential stock movement.
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), indicating positive earnings outlook and potential for stock price increase.
The upgrade to Zacks Rank #2 signals increased confidence in Adaptive Biotechnologies' earnings, likely boosting demand for the stock and potentially driving its price up.
Adaptive Biotechnologies will hold its Q4 2024 results conference call on February 11, 2025, at 4:30 PM ET, featuring key executives and analysts from various firms.
The upcoming conference call will provide key insights into Adaptive Biotechnologies' Q4 2024 performance, impacting investor sentiment and stock valuation based on financial health and future outlook.
Adaptive Biotechnologies reported its financial results for Q4 and full year 2024, focusing on leveraging the adaptive immune system for clinical diagnostics and treatments.
Adaptive Biotechnologies' financial results indicate performance trends that could influence stock valuation, investor sentiment, and future funding opportunities.
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
1 month agoAdaptive Biotechnologies (ADPT) reported its quarterly performance for December 2024, with key metrics available for comparison against Wall Street estimates and previous year's results.
The performance metrics of Adaptive Biotechnologies against Wall Street estimates and past results indicate growth potential or risks, impacting investor sentiment and stock valuation.
Frequently Asked Questions About ADPT Stock
What is Adaptive Biotechnologies Corporation's (ADPT) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Adaptive Biotechnologies Corporation (ADPT) has a median price target of $10.00. The highest price target is $12.00 and the lowest is $7.00.
Is ADPT stock a good investment in 2025?
According to current analyst ratings, ADPT has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ADPT stock?
Wall Street analysts predict ADPT stock could reach $10.00 in the next 12 months. This represents a 18.8% increase from the current price of $8.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Adaptive Biotechnologies Corporation's business model?
The company develops and commercializes clinical products that leverage its immunoSEQ technology, which sequences T-cell and B-cell receptors to provide insights into the adaptive immune system. Adaptive Biotechnologies generates revenue through partnerships with pharmaceutical companies and research organizations, focusing on diagnostics and treatments for diseases like cancer and autoimmune conditions.
What is the highest forecasted price for ADPT Adaptive Biotechnologies Corporation?
The highest price target for ADPT is $12.00 from Sung Ji Nam at Scotiabank, which represents a 42.5% increase from the current price of $8.42.
What is the lowest forecasted price for ADPT Adaptive Biotechnologies Corporation?
The lowest price target for ADPT is $7.00 from David Westenberg at Piper Sandler, which represents a -16.9% decrease from the current price of $8.42.
What is the overall ADPT consensus from analysts for Adaptive Biotechnologies Corporation?
The overall analyst consensus for ADPT is bullish. Out of 8 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are ADPT stock price projections?
Stock price projections, including those for Adaptive Biotechnologies Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
